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ABSTRACT
Objectives: Lymphedema of the arm is a devastating complication of breast carcinoma treatment. There is a lack of research on the risk factors and 
methods of preventing upper limb lymphedema after breast carcinoma treatment. The aims of the study are to identify the prevalence and risk factors 
for upper limb lymphedema in patients attending a tertiary cancer care center in India.
Methods: 199 patients who attended the outpatient department of radiotherapy of IPGMER and SSKM, after undergoing surgical treatment for breast 
cancer between November 2014 to May 2016 were examined for the presence of lymphedema and its risk factors were analyzed. Lymphedema was 
defined as being present when there is an increase of >5% sum difference in the arm circumferences measured at different levels of both the upper 
limbs.
Results: Of the 199 patients analyzed, 85 (42.7%) patients were found to have lymphedema. The prevalence of lymphedema was 25% in those who 
underwent surgery alone and 54% in those who underwent chest wall radiotherapy also. Locally advanced stage of the disease, body mass index 
>25 kg/m2, number of lymph nodes removed during surgery, and adjuvant radiotherapy were found to be significant risk factors for the development 
of lymphedema.
Conclusion: Based on the results of this study, we recommend weight reduction and more judicious axillary lymph node dissection and use of 
postoperative radiotherapy as methods to prevent breast cancer-associated lymphedema in the tertiary cancer care centers in India.
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INTRODUCTION
Cancer is a kind of disease in which a group of cells undergoes 
uncontrollable cell growth, invasion, or metastasis. Worldwide, breast 
cancer is the second most common type cancer after lung cancer. 
Breast cancer is the most frequently diagnosed cancer in urban woman. 
Due to advances in early detection and application of multimodality 
treatment, breast cancer mortality rates have declined in recent years. 
Although an increasing number of patients are surviving long term 
after multimodality treatment, some women develop lymphedema of 
the ipsilateral arm after treatment. Those patients with arm edema 
secondary to breast cancer treatment experience a substantial degree 
of functional impairment, psychological morbidity, and diminished 
quality of life [1-5].
Most studies on lymphedema concentrate on its management 
emphasizing the use of compression garments, bandaging, pumps, 
massage, and exercise. Many researchers have analyzed the clinical 
and pathologic risk factors for lymphedema. Even though locoregional 
therapy for breast in the form of surgery and radiotherapy are well-
established risk factors of lymphedema of the arm, majority of the other 
risk factors still remain unclear [6-12].
Arm edema in breast cancer patients occurs due to interruption of 
axillary lymphatic system, mainly due to surgery and radiotherapy, 
which results in the accumulation of fluid in subcutaneous tissues in 
the arm with decreased distensibility of tissues around the joints and 
increased weight of the arm. Other reported predisposing risk factors 
include age, infection, obesity, other preexisting comorbid conditions 
(such as cardiovascular conditions), and the surgical technique used, 
but all the reports are conflicting [13].
The overall treatment approach toward breast cancer has changed in 
the recent past and the present trend is toward less radical surgical 
procedures and more conformal radiation therapy. Still the risk of 
lymphedema persists for every patient who had undergone any form 
of locoregional therapy to the breast and there may also be other 
predisposing factors in lymphedema development which are not yet 
present in the available guidelines.
METHODS
199 patients attending radiotherapy outpatient department of IPGMER 
and SSKM, Kolkata during November 2014 - May 2016 were included 












This study included 217 subjects, after informing them about the 
purpose of the study and taking prior consent from them. Patient’s 
details including age, body surface area, menopausal status, follow-up 
period, stage of the disease, and treatment received were recorded in a 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i6.16118
Research Article
241
Asian J Pharm Clin Res, Vol 10, Issue 6, 2017, 240-242
 Gopal et al. 
pro forma. Details of chemotherapy (regimens and number of cycles) 
and radiotherapy (technique, dose, and extent of radiation) were also 
collected.
The circumference of both the upper limbs was measured in 6 places-
armpit, halfway down the upper arm, elbow, halfway down the forearm, 
wrist, and hand with the thumb. In each area, a percent difference 
was calculated standardizing the absolute differences between 2 
circumferences by the largest circumference. The total sum of the 
percent differences between the two upper limbs was used to define 
the presence of lymphedema. All patients having a sum of percent 
differences of >5% were classified as having lymphedema [14]. All 
measurements were taken by the same investigator who was trained 
and practiced in this technique. Since there was a departmental 
protocol of measuring mid-arm and mid-forearm measurements of all 
breast cancer patients on follow-up, all measurements were recorded 
independently taken at the previous visits to reduce bias.
All patients attending our outpatient department during the study 
period who had finished 6 months of follow-up after the date of 
surgery for breast cancer were enrolled in the study. Patients who had 
lymphedema during any of their follow-up visits were not examined 
again and those who did not have lymphedema at the time of initial 
examination after enrollment were also examined during their 
follow-up visits for the development of lymphedema till the end of 
study period.
Statistical analysis was done using Statistical Package for the Social 
Sciences version 15 and the statistical significance was calculated using 
the Chi-square test.
RESULTS
217 patients were examined during the study period. However, 
18 of them were excluded from the final analysis due to inadequate 
documentation. Tracing of data of the final 199 patients were nearly 
total.
The median age was 51 years and the median follow-up period was 
33 months. 43% of the patients had locally advanced disease and 
44.2% patients had a body mass index (BMI) of >25 kg/m2. All but 
2 patients underwent MRM and the other 2 patients underwent radical 
mastectomy. The average number of nodes removed during surgery was 
13 (ranging from 4 to 33). 139 patients (70%) underwent radiotherapy 
using two-dimensional (2D) techniques for a total dose of 50 Gy in 
2 Gy per fraction and 162 (81%) patients received chemotherapy of 
different regimens.
The prevalence of lymphedema was observed to be 42.7% among all 
the patients after analysis. The prevalence of lymphedema was 25% in 
those who were treated with surgery alone and 54% in those who were 
treated with both surgery and radiotherapy. Lymphedema was noticed 
in 58% with locally advanced breast cancer, 58% with BMI >25 kg/m2, 
and in 60% who had got >10 lymph nodes dissected during surgery.
After the final analysis stage of the disease, BMI, addition of radiotherapy 
to surgery, and number of lymph nodes removed during surgery came 
out as statistically significant factors in univariate analysis (Tables 1-5).
DISCUSSION
Worldwide, breast cancer comprises 22.9% of all cancers in women. 
It is 100 times and more common in women than in men although 
men tend to have poorer outcomes due to delays in diagnosis. The 
incidence of breast cancer is rising in every country of the world, 
especially in developing countries such as India [15]. Breast cancer-
related secondary lymphedema presents a significant problem for the 
affected patients. Patients and patient’s family expect the patient to lead 
a normal life after going through all the trauma of cancer treatment. 
Apart from local recurrence and distant recurrence, gross lymphedema 
of the arm is one of the most dreadful complications which can arise 
after breast cancer treatment which will result in significant reduction 
in	 the	quality	of	 the	 life	of	 the	patients.	Furthermore,	 there	has	been	
virtually no systematic research in the area of preventive strategies for 
arm lymphedema associated with breast cancer treatment. Randomized 
control trials and well-conducted retrospective studies are needed to 
clearly evaluate the preventive measures and to assess the risk factors 
for the development of lymphedema.
Lymphedema can be defined as a pathologic state characterized by 
chronic inflammatory fibrosis and hypertrophy of the hypodermal 
and dermal connective tissue due to lymphatic blockage mainly 
due to surgery and radiotherapy [16]. Across a number of studies, 
lymphedema has been reported to occur approximately in 41% (range 
of 21-51%) of patients who undergo axillary radiotherapy in addition 
Table 1: Stage




Early breast cancer 78/113 (69) 35/113 (31)
Locally advanced breast 
cancer









<25	kg/m2 73/111 (66) 38/111 (34)
>25 kg/m2 41/88 (42) 47/88 (58)
114 85
The	Chi-square	statistic	is	7.3756	an	the	p<0.05	which	is	statistically	significant,	
BMI: Body mass index
Table 3: Radiotheraphy




No 45/60 (75) 15/60 (25)









No 20/37 (54) 17/37 (46)
Yes 94/162 (58) 68/162 (42)
114 85
The Chi-square statistic is 0.1941 and the p>0.05 which is not statistically 
significant
Table 4: Number of lymph nodes removed






<10 47/58 (81) 11/58 (19)
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to surgery as opposed to approximately 17% (range 6-39%) of patients 
treated with surgery and no axillary radiotherapy [17]. There is wide 
variation in prevalence and it is due to lack of consensus regarding the 
clinical criteria, method of assessment, and timing of assessment for 
lymphedema.
During the era of radical mastectomy, the reported incidence of 
lymphedema varied from 49-63%. Subsequently, during the MRM era, 
the lymphedema prevalence has shown a decreasing trend and the 
reported rates of lymphedema following MRM varies from 24% to 28%. 
Postoperative radiotherapy can aggravate lymphedema by inducing 
fibrosis, scar formation, and radiodermatitis.
Various methods have been described in literature for assessment 
of lymphedema including volumetric methods (water displacement 
methods), serial circumferential measurement technique, magnetic 
resonance imaging, bioelectrical impedance, and tonometry [18,19]. 
Serial circumferential measurements were used in this study because 
of its simplicity and reproducibility.
A complete axillary lymph node dissection was considered to be a critical 
component of surgical cure of breast cancer patients until recently. 
This changed when studies such as NSABP-04 [20] came out in which 
the patients were randomized to radical mastectomy, total mastectomy 
with radiotherapy to regional lymphatics, or total mastectomy with 
observation of axillary lymphatics and delayed axillary lymph node 
dissection showed no benefit over axillary surgery. Recently, lymphatic 
mapping and sentinel lymph node biopsy is replacing axillary lymph node 
dissection as the staging procedure in clinically node-negative woman.
Even though this is the development regarding management of axilla 
in the developed countries, we are still devoid of such facilities such as 
sentinel lymph node biopsy in most of our government centers. Hence, 
it is appropriate to think about the other preventable risk factors which 
can be applied in daily life practice. Apart from surgery and radiotherapy, 
many other risk factors are described in literature such as age, presence 
of comorbid conditions, infection, obesity, stage of disease, and systemic 
therapy. In this study, we tried to assess some of those risk factors.
Apart from the conventional 2D radiotherapy treatment, image-
based three-dimensional (3D) techniques such as 3D conformal 
radiation therapy, intensity-modulated radiation therapy, and image-
guided radiation therapy have evolved. These technologies help in 
reducing doses to normal tissues including the lymphatic tissues. 
This should lead to reduction of fibrosis and other changes, which 
contribute to lymphedema. This should in turn reduce the incidence 
of lymphadenopathy in such patients. However, till date, there is no 
published	data	validating	this.	Furthermore,	the	normal	conventional	
fields irradiate level I and II axillary lymph nodes. Hence, the need 
for extensive lymph node dissection has also been questioned with 
the concept of axillary nodal sampling in clinically node-negative 
patients.
The limitations of the study are its study design (longer follow-up 
needed for patients with short follow-up), small number of patients, 
and a lack of standardized method of diagnosing lymphedema. One 
major possible confounding factor is the role of chemotherapy and the 
use of anthracyclines in the development of lymphedema which was 
shown	as	a	risk	factor	in	some	previous	studies.	Furthermore,	patients	
who underwent simple mastectomy and breast conserving surgery 
were excluded which could be a confounding factor and there could 
be patients who will not turn up for regular follow-up after the initial 
treatment, whose numbers may be missing from this study, which could 
be also a confounding factor.
Despite limited numbers and many limitations, this study clearly 
proves that locally advanced stage, obesity, higher number of lymph 
nodes resected, and addition of radiotherapy increases the chances for 
lymphedema.
CONCLUSION
In the postradical mastectomy era, the incidence rates of lymphedema 
have	shown	a	decreasing	trend.	Furthermore,	in	the	current	scenario,	
the radiation therapy is also gradually changing from 2D radiotherapy 
to 3D radiotherapy. Does this change from 2D to 3D have a say on the 
prevalence of lymphedema in patients who had undergone surgery? 
The answer of this question will remain unanswered till further studies 
are conducted. Based on our study, we recommend weight reduction 
and judicial use of radiotherapy whenever feasible in the tertiary 
cancer	care	centers	of	our	country.	Furthermore,	extensive	lymph	node	
dissection is questioned in node-negative patients with the concept of 
axillary	lymph	node	sampling	coming	up.	Furthermore,	the	involvement	
of a physical medicine specialist in the holistic management of every 
breast carcinoma patient soon after diagnosis is very important.
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